ASSESS: A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg doses administered orally once daily or glatiramer acetate administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis
Aims: The purpose of this study is to compare 2 doses of fingolimod to copaxone and to evaluate the efficacy and safety of fingolimod 0.25mg
Principal Investigator: Afif Hentati, MD
IRB Approval Number: EH12-289
Funding Source: Novartis
Contact: Please call 847.570.1439 with questions regarding the study
Open to Enrollment: Yes

H.P. Acthar Gel Prospective Registry: A Prospective Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis (MS) Relap
Aims: This study aims to characterize the patient population and describe MS exacerbation recovery, treatment patterns and safety outcomes in patients who receive Acthar Gel to treat acute MS exacerbations.
Principal Investigator: Afif Hentati, MD
IRB Approval Number: EH15-398
Contact: Please call 847.570.1439 with questions regarding the study

An Evaluation of Viral Prevalence and Activity in Patients with Multiple Sclerosis
Aims: The purpose of this study is to investigate the relationship between viral infection, immune activation, and development of Multiple Sclerosis (MS). Specifically, this study will determine the virus levels, viral immune activity, and immunity type in MS patients and compare them to individuals without MS.
Principal Investigator: Susan Rubin, MD
IRB Approval Number: EH16-204
Contact: Please call 847.503.4344 with questions regarding the study

A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis
Aims: The purpose of this study is to evaluate the long-term safety and effectiveness of an investigational oral medication, ALKS 8700, for up to 96 weeks of treatment in adult subjects with Relapsing Remitting Multiple Sclerosis (RRMS).
Principle Investigator: Afif Hentati, MD
IRB Approval Number: EH16-142
Contact: Please call 847.570.1439 with questions regarding the study